$2.27
-0.04 (-1.73%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where XBIT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 3 with posted results
Held by 6 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Squarepoint Ops LLC, Qube Research & Technologies Ltd, CITADEL ADVISORS LLC, +1 more) · FINRA short interest 7.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for EfficacyNCT06526377Percentage of participants achieving ASAS40.Randomized · Quadruple-masked · Treatment | Phase 2 | Not yet recruiting | Drug: vilamakitug, placebo | Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA, Nr-axSpA | 150 | Sep 2028 | ≤ 773 d | 2026-05-14 |
| Natrunix in Combination With Methotrexate for Rheumatoid Arthritis TreatmentNCT06590090ACR 20 responseRandomized · Triple-masked · Treatment | Phase 2 | Not yet recruiting | Biological: Natrunix 400 mg · Drug: Placebo, Methotrexate (MTX) | Rheumatoid Arthritis | 108 | 2027-01-15 | in 149 d | 2025-12-09 |
| Natrunix or Placebo in Combination With Methotrexate in Rheumatoid ArthritisNCT05363891ACR 20 response rate at 12 weeks.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Natrunix, Placebo | Rheumatoid Arthritis | 243 | 2024-10-31actual | — | 2025-01-16 |
| XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic CancerNCT04825288results2026-08-04To Establish the Maximum Tolerated Dose (MTD) of XB2001 as Measured by Dose-Limiting Toxicity (DLT), in Combination With ONIVYDE + LV + 5-FU Chemotherapy Regimen in Patients With Advanced Pancreatic Cancer.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg, Phase II: XB2001 1000 mg, Phase II: Placebo | Pancreatic Cancer | 76 | 2023-10-26actual | — | 2026-08-04 |
| Hutrukin to Analyze Safety and PK in Healthy VolunteersNCT05098080Number of subjects with treatment related adverse events assessed according to CTCAE v5.0 of one single intravenous dose of HutrukinTM in healthy subjects at each dose level.Randomized · Open-label · Treatment | Phase 1 | Completed | Biological: Hutrukin, Placebo | Pharmacokinetics | 24 | 2023-10-24actual | — | 2024-07-23 |
| Natrunix Versus Methotrexate in Rheumatoid ArthritisNCT05363917ACR 50 response rate at 12 weeks.Randomized · Double-masked · Treatment | Phase 2 | Unknown status | Drug: Natrunix with MTX placebo (+folate), Natrunix placebo with MTX (+folate) | Rheumatoid Arthritis | 150 | 2022-12-15 | — | 2022-05-06 |
| Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy VolunteersNCT05099510results2026-08-14Number of Participants With Treatment Emergent Adverse EventsRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: Natrunix, Placebo | Pharmacokinetics | 24 | 2022-08-08actual | — | 2026-08-14 |
| Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.NCT02357966results2024-11-21Number of Participants Who Experienced Dose-limiting ToxicitiesRandomized · Double-masked · Treatment | Phase 1/2 | Completed | Biological: 514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II · Other: Placebo plus standard IV antibiotic treatment, Placebo plus standard IV antibiotic treatment: Phase II | Staphylococcus Aureus Bacteremia | 52 | Dec 2016actual | — | 2026-02-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19